{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:33:36Z","timestamp":1784151216749,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.remnie.2025.500161","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:32:05Z","timestamp":1745940725000},"page":"500161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III"],"prefix":"10.1016","volume":"44","author":[{"given":"I.","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Arcocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Quincoces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500161_bib0005","article-title":"Alpha Atlas: mapping global production of \u03b1-emitting radionuclides for targeted alpha therapy","volume":"142\u2013143","author":"Tosato","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.remnie.2025.500161_bib0010","unstructured":"Search and plot nuclear structure and decay data interactively. NuDat, (s. f.). Available from: https:\/\/www.nndc.bnl.gov\/nudat3\/."},{"key":"10.1016\/j.remnie.2025.500161_bib0015","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.119.230961","article-title":"Total-body PET and highly stable chelators together enable meaningful 89 Zr-antibody PET studies up to 30 days after injection","author":"Berg","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500161_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.119.239558","article-title":"The role of 89 Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals","volume":"62","author":"Van Dongen","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41181-024-00258-y","article-title":"Good practices for 89Zr radiopharmaceutical production and quality control","volume":"9","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.remnie.2025.500161_bib0030","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abe5fc","article-title":"Positron range-free and multi-isotope tomography of positron emitters","volume":"66","author":"Beekman","year":"2021","journal-title":"Phys Med Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25112626","article-title":"Production and semi-automated processing of 89Zr using a commercially available TRASIS MiniAiO module","volume":"25","author":"Gaja","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.remnie.2025.500161_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2017.03.004","article-title":"Production of Zr-89 using sputtered yttrium coin targets","volume":"50","author":"Queern","year":"2017","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00259-009-1263-1","article-title":"p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging","volume":"37","author":"Perk","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500161_bib0050","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-05-2137","article-title":"Performance of immuno\u2013positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients","volume":"12","author":"B\u00f6rjesson","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40336-021-00462-9","article-title":"89Zr-PET imaging in humans: a systematic review","volume":"10","author":"De Feo","year":"2022","journal-title":"Clin Transl Imaging."},{"key":"10.1016\/j.remnie.2025.500161_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.882541","article-title":"PET imaging of acidic tumor environment with 89Zr-labeled pHLIP probes","volume":"12","author":"Bauer","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.remnie.2025.500161_bib0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2009.12.009","article-title":"89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft","volume":"46","author":"Oude Munnink","year":"2010","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.remnie.2025.500161_bib0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s41181-024-00320-9","article-title":"[ 89 Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors","volume":"9","author":"Sanwick","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.remnie.2025.500161_bib0075","article-title":"[89Zr]ZrCl4 for direct radiolabeling of DOTA-based precursors","volume":"136\u2013137","author":"Lyashchenko","year":"2024","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/molecules29010185","article-title":"From bench to bedside: patient-oriented radiopharmaceutical development in nuclear medicine based on the example of [89Zr]Zr-PSMA-DFO","volume":"29","author":"Schom\u00e4cker","year":"2023","journal-title":"Molecules."},{"key":"10.1016\/j.remnie.2025.500161_bib0085","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","article-title":"89 Zr-cetuximab PET imaging in patients with advanced colorectal cancer","volume":"6","author":"der Houven","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.remnie.2025.500161_bib0090","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of Zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: a theragnostic approach","volume":"8","author":"Even","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.remnie.2025.500161_bib0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nucmedbio.2013.01.007","article-title":"Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas","volume":"40","author":"Bhattacharyya","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.remnie.2025.500161_bib0100","doi-asserted-by":"crossref","first-page":"17117","DOI":"10.18632\/oncotarget.24965","article-title":"89Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I","volume":"9","author":"Chekol","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.remnie.2025.500161_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2024.111379","article-title":"Preclinical studies and absorbed dose estimation of [89Zr]Zr-DFO-Bevacizumab for PET imaging of VEGF-expressing tumors","volume":"210","author":"Zolghadri","year":"2024","journal-title":"Appl Radiat Isot."},{"key":"10.1016\/j.remnie.2025.500161_bib0110","unstructured":"Zirconium Zr 89 Bevacizumab Positron Emission Tomography in Imaging Tumor Angiogenesis in Patients with Inflammatory Breast Cancer Receiving Preoperative Chemotherapy - NCI, (n.d.). https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2015-01107 (accessed March 11, 2025)."},{"key":"10.1016\/j.remnie.2025.500161_bib0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[ 89 Zr]Trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol Imaging Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7150\/thno.37098","article-title":"ImmunoPET predicts response to Met-targeted radioligand therapy in models of pancreatic cancer resistant to Met kinase inhibitors","volume":"10","author":"Escorcia","year":"2020","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.remnie.2025.500161_bib0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-10-1088","article-title":"VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment","volume":"71","author":"Nagengast","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.remnie.2025.500161_bib0130","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-17-0311","article-title":"89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors","volume":"23","author":"Bensch","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0135","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour targeting and radiation dose of radioimmunotherapy with 90 Y-rituximab in CD20+ B-cell lymphoma as predicted by 89 Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500161_bib0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron emission tomography\/computed tomography with 89 Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.remnie.2025.500161_bib0145","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.115.154401","article-title":"TGF-b Antibody uptake in recurrent high-grade glioma imaged with 89 Zr-fresolimumab PET","volume":"56","author":"Den Hollander","year":"2015","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0150","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","article-title":"Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer","volume":"41","author":"Pandit-Taskar","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500161_bib0155","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-15-0552","article-title":"A phase I\/II study for analytic validation of 89Zr-J591 ImmunoPET as a molecular imaging agent for metastatic prostate cancer","volume":"21","author":"Pandit-Taskar","year":"2015","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0160","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-human imaging with 89 Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12149-018-1312-6","article-title":"Phase I\/IIa PET imaging study with 89 zirconium labeled anti-PSMA minibody for urological malignancies","volume":"33","author":"Joraku","year":"2019","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0170","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.5b00128","article-title":"Novel bifunctional cyclic chelator for 89 Zr labeling\u2013radiolabeling and targeting properties of RGD conjugates","volume":"12","author":"Zhai","year":"2015","journal-title":"Mol Pharm."},{"key":"10.1016\/j.remnie.2025.500161_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.11.005","article-title":"Zr for antibody labeling and in vivo studies \u2013 A comparison between liquid and solid target production","volume":"58","author":"Dias","year":"2018","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.remnie.2025.500161_bib0185","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1076210","article-title":"Astatine-211 based radionuclide therapy: current clinical trial landscape","volume":"9","author":"Albertsson","year":"2023","journal-title":"Front Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41181-024-00298-4","article-title":"Astatine-211 radiolabelling chemistry: from basics to advanced biological applications","volume":"9","author":"Vanermen","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"10.1016\/j.remnie.2025.500161_bib0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","article-title":"Production, purification and availability of 211At: near term steps towards global access","volume":"100\u2013101","author":"Feng","year":"2021","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500161_bib0200","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12149-021-01612-9","article-title":"Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-024-00257-z","article-title":"Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial","volume":"9","author":"Naka","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"10.1016\/j.remnie.2025.500161_bib0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169434","article-title":"Comparison of the therapeutic effects of [211At]NaAt and [131I]NaI in an NIS-expressing thyroid cancer mouse model","volume":"23","author":"Watabe","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.remnie.2025.500161_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100757","article-title":"Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [211At] NaAt in mice: a revisit","volume":"13","author":"Liu","year":"2020","journal-title":"Transl Oncol."},{"key":"10.1016\/j.remnie.2025.500161_bib0220","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-22-0400","article-title":"Preclinical development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma","volume":"28","author":"Batra","year":"2022","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0225","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","article-title":"Preclinical evaluation of the acute radiotoxicity of the \u03b1-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice","volume":"12","author":"Sudo","year":"2019","journal-title":"Transl Oncol."},{"key":"10.1016\/j.remnie.2025.500161_bib0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500161_bib0235","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40658-020-00326-7","article-title":"Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice","volume":"7","author":"Ukon","year":"2020","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.remnie.2025.500161_bib0240","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12149-022-01765-1","article-title":"Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"36","author":"Ukon","year":"2022","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0245","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1021\/pr801102c","article-title":"Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis","volume":"8","author":"Miguet","year":"2009","journal-title":"J Proteome Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0250","article-title":"cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.remnie.2025.500161_bib0255","article-title":"Astatine-211 based radionuclide therapy: Current clinical trial landscape","volume":"9","author":"Larsen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.remnie.2025.500161_bib0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.remnie.2025.500161_bib0265","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood.2019001250","article-title":"The \u03b1-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model","volume":"134","author":"O\u2019Steen","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2025.500161_bib0270","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0307543","article-title":"A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial","volume":"19","author":"Aneheim","year":"2024","journal-title":"PLoS One."},{"key":"10.1016\/j.remnie.2025.500161_bib0280","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijrobp.2007.06.023","article-title":"Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice","volume":"69","author":"Palm","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.remnie.2025.500161_bib0285","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2967\/jnumed.120.249300","article-title":"Utility of 211 At-trastuzumab for the treatment of metastatic gastric cancer in the liver: evaluation of a preclinical \u03b1-radioimmunotherapy approach in a clinically relevant mouse model","volume":"62","author":"Li","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0290","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","article-title":"Prostate cancer\u2013specific PET radiotracers: a review on the clinical utility in recurrent disease","volume":"8","author":"Evans","year":"2018","journal-title":"Pract Radiat Oncol."},{"key":"10.1016\/j.remnie.2025.500161_bib0295","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","article-title":"Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound","volume":"50","author":"Watabe","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500161_bib0300","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41598-021-04339-9","article-title":"Feasibility of a novel photoproduction of 225 Ac and 227 Th with natural thorium target","volume":"12","author":"Ju","year":"2022","journal-title":"Sci Rep."},{"key":"10.1016\/j.remnie.2025.500161_bib0305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apradiso.2016.10.015","article-title":"A radium-223 microgenerator from cyclotron-produced trace Actinium-227","volume":"119","author":"Abou","year":"2017","journal-title":"Appl Radiat Isot."},{"key":"10.1016\/j.remnie.2025.500161_bib0310","first-page":"385","article-title":"Radioisotope generators of short-lived \u03b1-emitting radionuclides promising for use in nuclear medicine","volume":"56","author":"Guseva","year":"2014","journal-title":"Orig Russ Text."},{"key":"10.1016\/j.remnie.2025.500161_bib0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1524\/ract.2011.1804","article-title":"Chromatographic generator systems for the actinides and natural decay series elements","volume":"99","author":"McAlister","year":"2011","journal-title":"Radiochim Acta."},{"key":"10.1016\/j.remnie.2025.500161_bib0320","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.apradiso.2018.12.012","article-title":"The potential radio-immunotherapeutic \u03b1-emitter 227 Th \u2013 part I: Standardisation via primary liquid scintillation techniques and decay progeny ingrowth measurements","volume":"145","author":"Collins","year":"2019","journal-title":"Appl Radiat Isot."},{"key":"10.1016\/j.remnie.2025.500161_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2024.111326","article-title":"Activity standard and calibrations for 227Th with ingrowing progeny","volume":"209","author":"Bergeron","year":"2024","journal-title":"Appl Radiat Isot."},{"key":"10.1016\/j.remnie.2025.500161_bib0330","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acs.jmedchem.4c02423","article-title":"Synthesis and evaluation of a bifunctional chelator for thorium-227 targeted radiotherapy","volume":"68","author":"Woods","year":"2025","journal-title":"J Med Chem."},{"key":"10.1016\/j.remnie.2025.500161_bib0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133419","article-title":"Efficacy of a HER2-targeted thorium-227 conjugate in a HER2-positive breast cancer bone metastasis model","volume":"15","author":"Karlsson","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.remnie.2025.500161_bib0340","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1021\/acs.inorgchem.2c04460","article-title":"Chelation behaviors of 3,4,3-LI(1,2-HOPO) with lanthanides and actinides implicated by molecular dynamics simulations","volume":"62","author":"Wang","year":"2023","journal-title":"Inorg Chem."},{"key":"10.1016\/j.remnie.2025.500161_bib0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/cplu.202100083","article-title":"Combining the best of two chelating titans: a hydroxypyridinone-decorated macrocyclic ligand for efficient and concomitant complexation and sensitized luminescence of f-elements","volume":"86","author":"Arnedo-Sanchez","year":"2021","journal-title":"Chempluschem."},{"key":"10.1016\/j.remnie.2025.500161_bib0350","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2191-219X-1-18","article-title":"Experimental \u03b1-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab","volume":"1","author":"Abbas","year":"2011","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0355","first-page":"672","article-title":"227 Th-labeled Anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-hodgkin lymphoma: a first-in-human, phase i study","volume":"36","author":"Lind\u00e9n","year":"2021","journal-title":"Cancer Biother Radiopharm."},{"key":"10.1016\/j.remnie.2025.500161_bib0360","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical efficacy of the auristatin-based antibody\u2013drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.remnie.2025.500161_bib0365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/ph12040155","article-title":"Synergistic effect of a HER2 targeted thorium-227 conjugate in combination with olaparib in a BRCA2 deficient Xenograft model","volume":"12","author":"Wickstroem","year":"2019","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.remnie.2025.500161_bib0370","unstructured":"Study Details | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT04147819 (accessed March 10, 2025)."},{"key":"10.1016\/j.remnie.2025.500161_bib0375","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijrobp.2019.06.2508","article-title":"Preclinical combination studies of an FGFR2 targeted thorium-227 conjugate and the ATR inhibitor BAY 1895344","volume":"105","author":"Wickstroem","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.remnie.2025.500161_bib0380","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines."},{"key":"10.1016\/j.remnie.2025.500161_bib0385","first-page":"497","article-title":"Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy","volume":"35","author":"Hagemann","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"10.1016\/j.remnie.2025.500161_bib0390","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.118.223701","article-title":"Synergistic effect of a mesothelin-targeted 227 Th conjugate in combination with DNA Damage response inhibitors in ovarian cancer xenograft models","volume":"60","author":"Wickstroem","year":"2019","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500161_bib0395","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002387","article-title":"Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy","volume":"9","author":"Lejeune","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.remnie.2025.500161_bib0400","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-22-0808","article-title":"A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies","volume":"22","author":"Zitzmann-Kolbe","year":"2023","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.remnie.2025.500161_bib0405","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1071086","article-title":"Targeted thorium-227 conjugates as treatment options in oncology","volume":"9","author":"Karlsson","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.remnie.2025.500161_bib0410","first-page":"497","article-title":"Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy","volume":"35","author":"Hagemann","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"10.1016\/j.remnie.2025.500161_bib0415","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1021\/acs.jmedchem.1c00762","article-title":"BAY-8400: a novel potent and selective DNA-PK inhibitor which shows synergistic efficacy in combination with targeted alpha therapies","volume":"64","author":"Berger","year":"2021","journal-title":"J Med Chem."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T15:39:56Z","timestamp":1751643596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2253808925000552"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500161","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500161","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500161"}}